Sold as Dyclone. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Dyclonine Hydrochloride (sold as Dyclone), with 0 new uses approved and 0 published complete response letters.
| Dyclonine vs. Tetracaine for Local Anesthesia in Unsedated GastroscopyGastrointestinal Symptoms · General Hospital of Shenyang Military Region | Not applicable | Not yet recruiting | Jul 8, 2026 |
| Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot StudyEsophagogastroduodensocopy (EGD) Procedure · Peking Union Medical College Hospital | Phase 4 | Active, not recruiting | Dec 4, 2025 |
| Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopyEsophagogastroduodensocopy (EGD) Procedure · Peking Union Medical College Hospital | Phase 4 | Not yet recruiting | Dec 11, 2024 |
| Nov 20, 2018 | DycloproANDA 200480 | Septodont | 0 | Marketed |
| — | DycloneNDA 9925 | Astrazeneca | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Astrazeneca